Therapeutic Area

Diffuse Large B-Cell Lymphoma

Therapeutic area intelligence for Diffuse Large B-Cell Lymphoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Merck →

Assets

Oncology →

Shikonin →

Recent signals(2)

ClinicalJune 20, 2026

Shikonin Induces Ferroptosis in DLBCL via lncRNA ADPGK-AS1 Downregulation

Shikonin suppresses DLBCL progression by inducing ferritinophagy and ferroptosis through lncRNA ADPGK-AS1 downregulation.

ClinicalJune 17, 2026

Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study

A Phase 2/3 study is evaluating zilovertamab vedotin in combination with standard care for rrDLBCL, with a protocol amendment discontinuing enrollment in one cohort.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diffuse Large B-Cell Lymphoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.